UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Tissue Penetration of Antifungal Agents

Clinical Microbiology Reviews, 2014-01, Vol.27 (1), p.68-88

2014

Volltextzugriff (PDF)

Observational Study of the Clinical Efficacy of Voriconazole and Its Relationship to Plasma Concentrations in Patients

Antimicrobial Agents and Chemotherapy, 2011-10, Vol.55 (10), p.4782-4788

2011

Volltextzugriff (PDF)

Imaging Findings in Acute Invasive Pulmonary Aspergillosis: Clinical Significance of the Halo Sign

Clinical infectious diseases, 2007-02, Vol.44 (3), p.373-379

2007

Volltextzugriff (PDF)

Voriconazole versus Amphotericin B for Primary Therapy of Invasive Aspergillosis

The New England journal of medicine, 2002-08, Vol.347 (6), p.408-415

2002

Volltextzugriff (PDF)

Early Serum Galactomannan Trend as a Predictor of Outcome of Invasive Aspergillosis

Journal of Clinical Microbiology, 2012-07, Vol.50 (7), p.2330-2336

2012

Volltextzugriff (PDF)

Early Proinflammatory Cytokines and C-Reactive Protein Trends as Predictors of Outcome in Invasive Aspergillosis

The Journal of infectious diseases, 2010-11, Vol.202 (9), p.1454-1462

2010

Volltextzugriff (PDF)

Association of Mannose-Binding Lectin Deficiency with Acute Invasive Aspergillosis in Immunocompromised Patients

Clinical infectious diseases, 2009-11, Vol.49 (10), p.1486-1491

2009

Volltextzugriff (PDF)

Voriconazole or amphotericin B as primary therapy yields distinct early serum galactomannan trends related to outcomes in invasive aspergillosis

PloS one, 2014-02, Vol.9 (2), p.e90176

2014

Volltextzugriff (PDF)

Safety of Voriconazole and Dose Individualization

Clinical infectious diseases, 2003-04, Vol.36 (8), p.1087-1088

2003

Volltextzugriff (PDF)

Neutrophils differentially attenuate immune response to Aspergillus infection through complement receptor 3 and induction of myeloperoxidase

Cellular microbiology, 2018-03, Vol.20 (3), p.e12798-n/a

2018

Volltextzugriff (PDF)

An elevated pro-inflammatory cytokine response is linked to development of amphotericin B-induced nephrotoxicity

Journal of antimicrobial chemotherapy, 2013-07, Vol.68 (7), p.1655-1659

2013

Volltextzugriff (PDF)

Pharmacokinetics and safety of 14 days intravenous voriconazole in allogeneic haematopoietic stem cell transplant recipients

Journal of antimicrobial chemotherapy, 2010-01, Vol.65 (1), p.107-113

2010

Volltextzugriff (PDF)

Observational Study of the Clinical Efficacy of Voriconazole and Its Relationship to Plasma Concentrations in Patients

Antimicrobial agents and chemotherapy, 2011-11, Vol.55 (11), p.5415-5415

2011

Volltextzugriff (PDF)

Mannose-Binding Lectin Deficiency - a Risk Factor for Invasive Aspergillosis in Immunocompromised Patients

Blood, 2008-11, Vol.112 (11), p.1465-1465

2008

Volltextzugriff (PDF)

Halo Sign and Improved Outcome

Clinical infectious diseases, 2007-06, Vol.44 (12), p.1666-1667

2007

Volltextzugriff (PDF)

Voriconazole or Amphotericin B as Primary Therapy Yields Distinct Early Serum Galactomannan Trends Related to Outcomes in Invasive Aspergillosis: e90176

PloS one, 2014-02, Vol.9 (2)

2014

Volltextzugriff (PDF)

Reply to Verweij et al

Clinical infectious diseases, 2007-06, Vol.44 (12), p.1667-1668

2007

Volltextzugriff (PDF)

Novel antifungal 2-aryl-1-(1 H-1,2,4-triazol-1-yl)butan-2-ol derivatives with high activity against Aspergillus fumigatus

Bioorganic & medicinal chemistry letters, 1996-08, Vol.6 (16), p.2031-2036

1996

Volltextzugriff (PDF)

Imaging Findings in Acute Invasive Pulmonary Aspergillosis : Clinical Significance of the Halo Sign. Commentary

Clinical infectious diseases, 2007, Vol.44 (3), p.373-381

2007

Volltextzugriff (PDF)

Efficacy of fluconazole (UK-49,858) against experimental aspergillosis and cryptococcosis in mice

Journal of antimicrobial chemotherapy, 1987-05, Vol.19 (5), p.663-670

1987

Volltextzugriff (PDF)

Mechanism of action of nikkomycin and the peptide transport system of Candida albicans

Journal of general microbiology, 1985-04, Vol.131 (4), p.775-780

1985

Volltextzugriff (PDF)

In Vitro Potency and in Vivo Activity of Azoles

Annals of the New York Academy of Sciences, 1988, Vol.544 (1), p.284-293

1988

Volltextzugriff (PDF)

Treatment of Scedosporiosis with Voriconazole: Clinical Experience with 107 Patients

Antimicrobial Agents and Chemotherapy, 2008-05, Vol.52 (5), p.1743-1750

2008

Volltextzugriff (PDF)

Strategy of Following Voriconazole versus Amphotericin B Therapy with Other Licensed Antifungal Therapy for Primary Treatment of Invasive Aspergillosis: Impact of Other Therapies on Outcome

Clinical infectious diseases, 2005-11, Vol.41 (10), p.1448-1452

2005

Volltextzugriff (PDF)

1 – 24 von 24

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(24)
Mit Volltextzugriff
(23)

Publikationsform

Artikel
(24)

Sprache

Englisch
(24)

Erscheinungsjahr

n.n

Thema

Science & Technology
(19)
Life Sciences & Biomedicine
(18)
Microbiology
(16)
Humans
(15)
Infectious Diseases
(13)
Biological And Medical Sciences
(12)
Female
(12)
Antifungal Agents - Therapeutic Use
(10)
Male
(10)
Medical Sciences
(10)
Aspergillosis
(9)
Adult
(8)
Aspergillosis - Drug Therapy
(8)
Middle Aged
(8)
Antibiotics. Antiinfectious Agents. Antiparasitic Agents
(7)
Aspergillus
(7)
Immunology
(7)
Pharmacology & Pharmacy
(7)
Pharmacology. Drug Treatments
(7)
Voriconazole
(7)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Tissue Penetration of Antifungal Agents

Observational Study of the Clinical Efficacy of Voriconazole and Its Relationship to Plasma Concentrations in Patients

Imaging Findings in Acute Invasive Pulmonary Aspergillosis: Clinical Significance of the Halo Sign

Voriconazole versus Amphotericin B for Primary Therapy of Invasive Aspergillosis

Early Serum Galactomannan Trend as a Predictor of Outcome of Invasive Aspergillosis

Early Proinflammatory Cytokines and C-Reactive Protein Trends as Predictors of Outcome in Invasive Aspergillosis

Association of Mannose-Binding Lectin Deficiency with Acute Invasive Aspergillosis in Immunocompromised Patients

Voriconazole or amphotericin B as primary therapy yields distinct early serum galactomannan trends related to outcomes in invasive aspergillosis

Safety of Voriconazole and Dose Individualization

Neutrophils differentially attenuate immune response to Aspergillus infection through complement receptor 3 and induction of myeloperoxidase

An elevated pro-inflammatory cytokine response is linked to development of amphotericin B-induced nephrotoxicity

Pharmacokinetics and safety of 14 days intravenous voriconazole in allogeneic haematopoietic stem cell transplant recipients

Observational Study of the Clinical Efficacy of Voriconazole and Its Relationship to Plasma Concentrations in Patients

Mannose-Binding Lectin Deficiency - a Risk Factor for Invasive Aspergillosis in Immunocompromised Patients

Halo Sign and Improved Outcome

Voriconazole or Amphotericin B as Primary Therapy Yields Distinct Early Serum Galactomannan Trends Related to Outcomes in Invasive Aspergillosis: e90176

Reply to Verweij et al

Novel antifungal 2-aryl-1-(1 H-1,2,4-triazol-1-yl)butan-2-ol derivatives with high activity against Aspergillus fumigatus

Imaging Findings in Acute Invasive Pulmonary Aspergillosis : Clinical Significance of the Halo Sign. Commentary

Efficacy of fluconazole (UK-49,858) against experimental aspergillosis and cryptococcosis in mice

Mechanism of action of nikkomycin and the peptide transport system of Candida albicans

In Vitro Potency and in Vivo Activity of Azoles

Treatment of Scedosporiosis with Voriconazole: Clinical Experience with 107 Patients

Strategy of Following Voriconazole versus Amphotericin B Therapy with Other Licensed Antifungal Therapy for Primary Treatment of Invasive Aspergillosis: Impact of Other Therapies on Outcome

Suchergebnisse filtern